# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Benjamin Franklin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN004-SYN
- Date: 2026-03-30
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lydia Penhallow, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week gout and blood pressure review; urology consultation today. **S**

## History of present illness

Mr. Franklin returns four weeks after starting allopurinol 100 mg and colchicine 0.6 mg daily and changing hydrochlorothiazide to losartan 50 mg. He has had no gout flare, no rash, and no diarrhea. His home blood pressure averages 136/80. He still has an interrupted stream, pain at the end of voiding, and pink urine after car journeys, and he gets up three times a night. He takes acetaminophen for the bladder pain about twice a week and no ibuprofen. He is drinking more water, about 1.5 L a day, and has cut back to one glass of wine with dinner. He saw the urologist this morning. **S**

| Element | Detail |
|---|---|
| Gout | No flare since starting allopurinol and colchicine |
| Medication tolerance | No rash, diarrhea, or muscle aches |
| Home blood pressure | Average 136/80 mmHg on losartan |
| Urinary symptoms | Interrupted stream, terminal pain, pink urine after car journeys; nocturia three times |
| Fluids and diet | About 1.5 L of water a day; one glass of wine with dinner |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Musculoskeletal | Negative | No joint pain or swelling |
| Genitourinary | Positive | Interrupted stream, terminal dysuria, intermittent pink urine, nocturia three times |
| Integumentary | Negative | No rash or itching on allopurinol |
| Gastrointestinal | Negative | No diarrhea or nausea on colchicine |
| Neurological | Negative | No dizziness on standing |

5 systems reviewed. **S**

## Current medications

- Losartan 50 mg oral tablet, one tablet by mouth daily **S**
- Allopurinol 100 mg oral tablet, two tablets (200 mg) by mouth daily **S**
- Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxis **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a day **S**
- Tamsulosin 0.4 mg oral capsule, one capsule by mouth at bedtime until surgery **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 138/80 mmHg; pulse 70 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 95.4 kg; BMI 31.2 kg/m². All vital signs are synthetic.

Serum urate: 7.6 mg/dL (high); Sodium: 139 mmol/L; Potassium: 4.4 mmol/L; Bicarbonate (total CO2): 24 mmol/L; BUN: 21 mg/dL; Creatinine: 1.34 mg/dL; eGFR: 55 mL/min/1.73 m² (low); Glucose: 96 mg/dL; Post-void residual volume by bladder ultrasound: 160 mL (high); Maximum urine flow rate (Qmax): 8.5 mL/s (low); IPSS: 16. All results are synthetic.

## Change since baseline

- Serum urate: 9.1 mg/dL (high) at baseline, 7.6 mg/dL (high) at this visit **S**
- Sodium: 140 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 4.4 mmol/L at this visit **S**
- Bicarbonate (total CO2): 25 mmol/L at baseline, 24 mmol/L at this visit **S**
- BUN: 22 mg/dL at baseline, 21 mg/dL at this visit **S**
- Creatinine: 1.36 mg/dL (high) at baseline, 1.34 mg/dL at this visit **S**
- eGFR: 54 mL/min/1.73 m² (low) at baseline, 55 mL/min/1.73 m² (low) at this visit **S**
- Glucose: 98 mg/dL at baseline, 96 mg/dL at this visit **S**
- IPSS: 16 at baseline, 16 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well, comfortable |
| Joints | No synovitis; no tophi; right first toe joint normal |
| Abdomen | Mild suprapubic tenderness; bladder not palpable |
| Cardiovascular | Regular rhythm; no edema |
| Skin | No rash |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Gout, on treat-to-target urate lowering** (M1A.0710). Serum urate 7.6 mg/dL, down from 9.1 but above the target of below 6. No flare and no allopurinol side effects. **S**
   - Increase allopurinol to 200 mg daily.
   - Continue colchicine 0.6 mg daily.
   - Serum urate in 2 to 5 weeks.
2. **Bladder stone** (N21.0). Urology confirms a single 2.6 cm bladder stone behind an obstructing prostate, with no bladder tumor on cystoscopy. **S**
   - Cystolitholapaxy with transurethral resection of the prostate booked in three weeks.
   - Aim for 2.5 to 3 L of fluid a day.
3. **Benign prostatic hyperplasia with outlet obstruction** (N40.1). IPSS 16, maximum flow 8.5 mL/s, and post-void residual 160 mL. A bladder stone caused by obstruction is an indication for surgery. **S**
   - Tamsulosin 0.4 mg at bedtime until surgery, as urology advised.
4. **Chronic kidney disease G3a A1** (N18.31). Four weeks after starting losartan, potassium 4.4 mmol/L and creatinine 1.34 mg/dL (eGFR 55), stable. **S**
   - Continue losartan.
   - Start atorvastatin 20 mg daily, recommended for adults over 50 with eGFR below 60; report muscle aches, since he also takes colchicine.
5. **Hypertension** (I10). Office 138/80 mmHg and home average 136/80 mmHg, improving but above 130/80. **S**
   - Continue losartan 50 mg; recheck after surgery.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Serum urate | Every 2 to 5 weeks while titrating; every 6 months once at target | Completed today | 7.6 mg/dL four weeks after starting allopurinol 100 mg; dose increased |
| Medication safety | Allopurinol hypersensitivity and colchicine tolerance | Every visit while titrating | Completed today | No rash, fever, diarrhea, or muscle symptoms |
| Laboratory | HLA-B*58:01 before allopurinol | Once, only in Southeast Asian or African American patients | Not indicated | Not of Southeast Asian or African ancestry |
| Medication safety | Flare prophylaxis | 3 to 6 months after starting urate-lowering therapy | Completed today | Colchicine 0.6 mg daily, week 4 |
| Laboratory | Potassium and creatinine 2 to 4 weeks after starting an ARB | Once after starting or titrating | Completed today | Potassium 4.4 mmol/L, creatinine 1.34 mg/dL, eGFR 55, four weeks after starting losartan |
| Examination | Office and home blood pressure | Every visit | Completed today | 138/80 mmHg in the office; home average 136/80 |
| Medication safety | Medication review for NSAIDs and dose adjustment for kidney function | Every visit | Completed today | No NSAIDs; allopurinol and colchicine doses suit eGFR 55 |
| Survey | IPSS | Baseline and every follow-up visit | Completed today | 16, moderate |
| Examination | Uroflowmetry and post-void residual | Before a procedure or when obstruction is suspected | Completed today | Maximum flow 8.5 mL/s; residual 160 mL |
| Referral | Urology evaluation of the bladder stone and hematuria | At diagnosis | Completed today | Seen today; cystoscopy shows no tumor; surgery booked |
| Laboratory | PSA | Only if it would change management | Not indicated | Age 76; it would not change the planned surgery, and resected tissue will be examined |
| Self-management | Fluid intake for stone prevention | Every visit | Completed today | About 1.5 L a day; goal 2.5 to 3 L |
| Self-management | Diet and alcohol for gout | Every visit | Completed today | Wine cut to one glass with dinner; fewer rich meals |

## Goal progress

- Serum urate below 6 mg/dL on allopurinol by the six-month review. In progress; target 2026-09-14. **S**
- Bladder stone removed and comfortable voiding with a normal post-void residual. In progress; target 2026-05-18. **S**
- No gout flare for six months after starting urate-lowering therapy. In progress; target 2026-09-14. **S**
- Blood pressure below 130/80 without dizziness. In progress; target 2026-09-14. **S**
- Urine output of at least 2.5 L a day and urine pH of 6.0 to 6.5. In progress; target 2026-09-14. **S**

## Medication changes

- Stopped: Allopurinol 100 mg oral tablet, one tablet by mouth daily **S**
- Started: Allopurinol 100 mg oral tablet, two tablets (200 mg) by mouth daily **S**
- Started: Tamsulosin 0.4 mg oral capsule, one capsule by mouth at bedtime until surgery **S**
- Started: Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**

## Guideline basis

- 2020 American College of Rheumatology Guideline for the Management of Gout (2020), American College of Rheumatology (Arthritis Care Res 2020;72(6):744-760)
- Medical Management of Kidney Stones: AUA Guideline (2014, amended 2019), American Urological Association
- EAU Guidelines on Urolithiasis (including bladder stones) (2025), European Association of Urology
- Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2023 amendment), American Urological Association
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney Int 2024;105(4S):S117-S314)
- CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, and benign prostatic hyperplasia monographs (2026), Aether Forge

## Follow-up

- Surgery in three weeks. Review four weeks after surgery with serum urate, a metabolic panel, urine tests, and a 24-hour urine collection. **S**
- Next scheduled visit 2026-05-18: review four weeks after stone removal and prostate resection, with urate titration and stone metabolic evaluation. **S**
